Adjuvant Selpercatinib Prolongs EFS Among Patients with Stage II or IIIA RET Fusion-Positive NSCLC By Ogkologos - June 2, 2026 37 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the LIBRETTO-432 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... September 29, 2022 Can Chemo Help KRAS Inhibitors Work Better Against Pancreatic Cancer? August 20, 2024 HER2-Low Expression Identified in Half of Solid Tumour Samples Tested for... September 13, 2023 ESMO Call for Cancer Care Safeguards Reflected in the EU’s Health... December 2, 2025 Load more HOT NEWS Responding to Coronavirus, Cancer Researchers Reimagine Clinical Trials Lack of Evidence for the Use of Telemedicine in the Prevention... Berry Recipes In memory of Dame Deborah James
